Compare Stocks: BNR, CLYM, IRWD, and STTK

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNR Burning Rock Biotech	$14.61 -2.6%	$12.62	$6.79 ▼ $41.72	$157.77M	1.29	32,689 shs	15,007 shs
CLYM Climb Bio	$10.29 -0.2%	$13.87	$1.63 ▼ $18.33	$592.17M	-0.04	1.41 million shs	987,712 shs
IRWD Ironwood Pharmaceuticals	$3.60 +0.3%	$4.12	$1.43 ▼ $5.78	$593.21M	0.21	2.33 million shs	1.22 million shs
STTK Shattuck Labs	$5.33 -2.9%	$6.69	$1.70 ▼ $8.33	$550.99M	1.09	1.71 million shs	1.20 million shs

10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNR Burning Rock Biotech	-2.60%	-3.75%	+25.95%	+52.19%	+72.08%
CLYM Climb Bio	-0.19%	-3.92%	-29.33%	-18.20%	+447.34%
IRWD Ironwood Pharmaceuticals	+0.28%	-4.00%	-13.67%	-6.98%	+143.24%
STTK Shattuck Labs	-2.91%	-5.83%	-14.03%	-24.61%	+185.03%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNR Burning Rock Biotech	$14.61 -2.6%	$12.62	$6.79 ▼ $41.72	$157.77M	1.29	32,689 shs	15,007 shs
CLYM Climb Bio	$10.29 -0.2%	$13.87	$1.63 ▼ $18.33	$592.17M	-0.04	1.41 million shs	987,712 shs
IRWD Ironwood Pharmaceuticals	$3.60 +0.3%	$4.12	$1.43 ▼ $5.78	$593.21M	0.21	2.33 million shs	1.22 million shs
STTK Shattuck Labs	$5.33 -2.9%	$6.69	$1.70 ▼ $8.33	$550.99M	1.09	1.71 million shs	1.20 million shs

10 Best Stocks to Own in Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNR Burning Rock Biotech	-2.60%	-3.75%	+25.95%	+52.19%	+72.08%
CLYM Climb Bio	-0.19%	-3.92%	-29.33%	-18.20%	+447.34%
IRWD Ironwood Pharmaceuticals	+0.28%	-4.00%	-13.67%	-6.98%	+143.24%
STTK Shattuck Labs	-2.91%	-5.83%	-14.03%	-24.61%	+185.03%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNR Burning Rock Biotech	1.00	Sell	N/A	N/A
CLYM Climb Bio	3.00	Buy	$27.62	168.37% Upside
IRWD Ironwood Pharmaceuticals	2.57	Moderate Buy	$6.23	73.15% Upside
STTK Shattuck Labs	3.08	Buy	$13.70	157.04% Upside

Current Analyst Ratings Breakdown

Latest BNR, CLYM, IRWD, and STTK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/12/2026	CLYM Climb Bio	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/11/2026	STTK Shattuck Labs	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$17.00
10/11/2026	STTK Shattuck Labs	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
10/8/2026	IRWD Ironwood Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold (C) ➝ Hold (C+)
10/5/2026	CLYM Climb Bio	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Strong-Buy	$34.00
10/2/2026	STTK Shattuck Labs	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$11.00 ➝ $14.00
10/2/2026	STTK Shattuck Labs	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$17.00 ➝ $19.00
9/25/2026	IRWD Ironwood Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold
9/16/2026	CLYM Climb Bio	Mizuho Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
9/11/2026	STTK Shattuck Labs	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/10/2026	BNR Burning Rock Biotech	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNR Burning Rock Biotech	$77.16M	1.99	N/A	N/A	$7.28 per share	2.01
CLYM Climb Bio	N/A	N/A	N/A	N/A	$3.36 per share	N/A
IRWD Ironwood Pharmaceuticals	$296.15M	2.01	$0.26 per share	13.95	($1.61) per share	-2.24
STTK Shattuck Labs	$1M	534.92	N/A	N/A	$1.30 per share	4.10

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNR Burning Rock Biotech	-$7.92M	-$0.87	N/A	N/A	N/A	-13.60%	-12.98%	-8.59%	11/17/2026 (Estimated)
CLYM Climb Bio	-$59.85M	-$0.83	N/A	N/A	N/A	N/A	-31.79%	-30.79%	11/11/2026 (Estimated)
IRWD Ironwood Pharmaceuticals	$24.02M	$0.77	4.60	N/A	N/A	33.36%	-58.38%	34.93%	11/9/2026 (Estimated)
STTK Shattuck Labs	-$48.81M	-$0.51	N/A	N/A	N/A	N/A	-43.57%	-40.90%	11/10/2026 (Estimated)

Latest BNR, CLYM, IRWD, and STTK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	CLYM Climb Bio	-$0.19	N/A	N/A	N/A	N/A	N/A
11/10/2026	Q3 2026	STTK Shattuck Labs	-$0.10	N/A	N/A	N/A	$0.03 million	N/A
11/9/2026	Q3 2026	IRWD Ironwood Pharmaceuticals	$0.3233	N/A	N/A	N/A	$119.99 million	N/A
9/10/2026	Q2 2026	BNR Burning Rock Biotech	-$2.2883	-$0.20	+$2.0883	-$0.25	$19.21 million	$19.84 million
8/11/2026	Q2 2026	STTK Shattuck Labs	-$0.1241	-$0.12	+$0.0041	-$0.12	N/A	N/A
8/6/2026	Q2 2026	CLYM Climb Bio	-$0.2093	-$0.18	+$0.0293	-$0.18	N/A	N/A
8/6/2026	Q2 2026	IRWD Ironwood Pharmaceuticals	$0.32	$0.31	-$0.01	$0.31	$114.84 million	$113.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNR Burning Rock Biotech	N/A	N/A	N/A	N/A	N/A
CLYM Climb Bio	N/A	N/A	N/A	N/A	N/A
IRWD Ironwood Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
STTK Shattuck Labs	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNR Burning Rock Biotech	N/A	3.05	2.90
CLYM Climb Bio	N/A	31.45	31.45
IRWD Ironwood Pharmaceuticals	N/A	6.06	6.06
STTK Shattuck Labs	N/A	27.59	27.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNR Burning Rock Biotech	30.03%
CLYM Climb Bio	69.76%
IRWD Ironwood Pharmaceuticals	N/A
STTK Shattuck Labs	58.74%

Insider Ownership

Company	Insider Ownership
BNR Burning Rock Biotech	30.30%
CLYM Climb Bio	2.60%
IRWD Ironwood Pharmaceuticals	9.30%
STTK Shattuck Labs	8.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNR Burning Rock Biotech	667	10.52 million	7.33 million	Not Optionable
CLYM Climb Bio	29	57.44 million	55.94 million	N/A
IRWD Ironwood Pharmaceuticals	100	165.24 million	149.87 million	Optionable
STTK Shattuck Labs	40	100.36 million	91.54 million	Optionable

BNR, CLYM, IRWD, and STTK Headlines

Recent News About These Companies

Shattuck Labs (NASDAQ:STTK) Upgraded at UBS Group

October 14 at 6:59 AM | marketbeat.com

Shattuck Labs (NASDAQ:STTK) Stock Falls 6.9% - Time to Sell?

October 13 at 2:59 PM | marketbeat.com

Shattuck Labs (NASDAQ:STTK) vs. Exicure (NASDAQ:XCUR) Critical Contrast

October 13 at 8:17 AM | americanbankingnews.com

Shattuck Labs Announces Two Poster Presentations at UEG Week 2026

October 13 at 8:00 AM | globenewswire.com

UBS Initiates Shattuck Labs at Buy With $17 Price Target

October 12 at 4:10 PM | marketscreener.comM

Shattuck Labs (STTK) Receives a Buy from Leerink Partners

October 5, 2026 | theglobeandmail.com

Shattuck Labs (NASDAQ:STTK) Stock Price Down 5.3% - What's Next?

October 5, 2026 | marketbeat.com

Needham & Company LLC Forecasts Strong Price Appreciation for Shattuck Labs (NASDAQ:STTK) Stock

October 4, 2026 | americanbankingnews.com

Shattuck Labs (NASDAQ:STTK) Stock Price Expected to Rise, Needham & Company LLC Analyst Says

October 2, 2026 | marketbeat.com

Shattuck Labs Plans Phase 2 Trial of Chronic Inflammatory Skin Disease Drug

October 1, 2026 | finance.yahoo.com

Shattuck Advances SL-325 Into Phase 2 Hidradenitis Suppurativa Trial

October 1, 2026 | rttnews.com

Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development

October 1, 2026 | globenewswire.com

Shattuck Labs (NASDAQ:STTK) Shares Up 11.9% - Time to Buy?

September 30, 2026 | marketbeat.com

Shattuck Labs, Inc. (NASDAQ:STTK) Receives Average Recommendation of "Buy" from Brokerages

September 25, 2026 | marketbeat.com

Shattuck Labs, Inc.(NasdaqGS:STTK) added to S&P Biotechnology Select Industry Index

September 21, 2026 | marketscreener.comM

Shattuck Labs Announces Participation in Upcoming September Investor Conferences

September 2, 2026 | globenewswire.com

Shattuck Labs: A Receptor-Side Bet On The TL1A Boom

September 1, 2026 | seekingalpha.com

Shattuck Labs, Inc. (STTK) is a Great Momentum Stock: Should You Buy?

August 20, 2026 | zacks.com

Wall Street Analysts Believe Shattuck Labs (STTK) Could Rally 85.31%: Here's is How to Trade

August 13, 2026 | zacks.com

Shattuck Labs Advances SL-325 Crohn’s Trial Toward a Key Value Milestone

August 12, 2026 | tipranks.com

Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights

August 11, 2026 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNR, CLYM, IRWD, and STTK Company Descriptions

Burning Rock Biotech NASDAQ:BNR

$14.61 -0.39 (-2.60%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$14.64 +0.04 (+0.24%)

As of 10/14/2026 07:30 PM Eastern

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.

Climb Bio NASDAQ:CLYM

$10.29 -0.02 (-0.19%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$10.30 +0.01 (+0.05%)

As of 10/14/2026 07:30 PM Eastern

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

Ironwood Pharmaceuticals NASDAQ:IRWD

$3.60 +0.01 (+0.28%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$3.57 -0.03 (-0.75%)

As of 10/14/2026 07:56 PM Eastern

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Shattuck Labs NASDAQ:STTK

$5.33 -0.16 (-2.91%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$5.33 0.00 (-0.08%)

As of 10/14/2026 07:56 PM Eastern

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BNR, CLYM, IRWD, and STTK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BNR, CLYM, IRWD, and STTK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BNR, CLYM, IRWD, and STTK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNR, CLYM, IRWD, and STTK Company Descriptions

Burning Rock Biotech NASDAQ:BNR

Climb Bio NASDAQ:CLYM

Ironwood Pharmaceuticals NASDAQ:IRWD

Shattuck Labs NASDAQ:STTK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BNR, CLYM, IRWD, and STTK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BNR, CLYM, IRWD, and STTK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BNR, CLYM, IRWD, and STTK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNR, CLYM, IRWD, and STTK Company Descriptions

Burning Rock Biotech NASDAQ:BNR

Climb Bio NASDAQ:CLYM

Ironwood Pharmaceuticals NASDAQ:IRWD

Shattuck Labs NASDAQ:STTK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools